Literature DB >> 12239755

[Prognostic importance of preoperative CEA in patients with colorectal cancer].

Angelo Turoldo1, Alessandro Balani, Monica Scaramucci, Francesca Babic, Daniela Guidolin, Gennaro Liguori.   

Abstract

Carcinoembryonic antigen is an acid glycoprotein, the levels of which may increase in patients with colorectal carcinoma. The prognostic significance of preoperative carcinoembryonic antigen levels and their relationship to other risk factors are still debatable issues. Among 512 patients operated on for colorectal cancer, whose preoperative carcinoembryonic antigen concentrations were evaluated, linear correlations were established between carcinoembryonic antigen overexpression and carcinoma staging, diameter and grading, though these were not statistically significant. Moreover, metastatic cancers were significantly more frequent in patients with increased plasma concentrations of the marker (> 60 ng/ml). There were no correlations between increased carcinoembryonic antigen levels and age, ploidy, or site and shape of the cancers. As regards survival, patients with normal preoperative carcinoembryonic antigen levels had a better prognosis in terms both of lower local recurrence rates and long- term survival. In addition. In Dukes stages B and C elevation of carcinoembryonic antigen above the cut-off point can be considered a significant prognostic factor capable of identifying a group of patients at high risk who may be candidates for aggressive adjuvant therapies and follow-up. The findings of this study suggest that preoperative carcinoembryonic antigen levels are of prognostic importance in relation both to cancer staging and to long-term survival, which may have significant clinical applications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239755

Source DB:  PubMed          Journal:  Chir Ital        ISSN: 0009-4773


  2 in total

1.  Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers.

Authors:  Ai-Sheng Ho; Chien-Hsin Chen; Chun-Chia Cheng; Chia-Chi Wang; Hua-Ching Lin; Tsai-Yueh Luo; Gi-Shih Lien; Jungshan Chang
Journal:  Oncotarget       Date:  2014-01-30

Review 2.  Cancer therapy using tumor-associated antigens to reduce side effects.

Authors:  David Siu
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 5.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.